|
시장보고서
상품코드
2109026
바이오인포매틱스 시장 : 제공 제품별, 기능별, 이용 사례별, 부문별, 최종 사용자별, 지역별 예측(-2031년)Bioinformatics Market by Offering [Software (Genomics, Multiomics, Proteomics), Services (Analysis, Sequencing)], Function (Variant & Structural Analysis), Use Case (Drug Discovery, Biomarker), End User (Pharma & Biotech, CROs) - Global Forecast to 2031 |
||||||
세계의 바이오인포매틱스 시장 규모는 2026년 186억 3,000만 달러에서 예측 기간 중에 CAGR 13.1%로 확대되어 2031년에는 344억 1,000만 달러에 이를 전망입니다.
유전체 연구, 정밀의료 이니셔티브, 신약 개발 프로그램의 급속한 진전에 따라, 복잡한 생물학적 데이터 세트를 저장, 관리, 분석 및 해석하는 바이오인포매틱스 플랫폼에 대한 수요가 크게 증가하고 있습니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2024-2031년 |
| 기준 연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 산정 단위 | 금액(100만/10억 달러) |
| 부문 | 제공 내용, 기능, 이용 사례, 최종 사용자 |
| 대상 지역 | 북미, 아시아태평양, 유럽, 남미, 중동 및 아프리카 |
제약·바이오기술 기업, 학술 기관, 의료 기관에서는 연구 가속화, 임상 의사 결정 개선, 치료법 개발 최적화를 도모하기 위해 통합형 바이오인포매틱스 솔루션 도입이 점점 더 확대되고 있습니다. 또한, 생명과학 연구 분야의 디지털 전환이 진전되고, 계산 생물학 및 클라우드 기반 바이오정보학 플랫폼에 대한 투자가 증가함에 따라 워크플로우 효율화가 도모되고, 대규모 데이터 공유가 가능해지며, 조직 간 공동 연구가 촉진되고 있습니다.
'엔드투엔드 솔루션은 바이오정보학 시장에서 가장 큰 소프트웨어 부문이 될 것으로 예측됩니다'
소프트웨어 기반의 엔드투엔드 솔루션은 예측 기간 동안 시장 점유율의 상당 부분을 차지할 것으로 예측됩니다. 이러한 우위는 생물학적 데이터의 수집, 저장, 처리, 분석, 시각화, 해석 및 보고를 포함하는 바이오인포매틱스 워크플로우 전체를 지원하는 통합 플랫폼에 대한 수요 증가에 의해 주도되고 있습니다. 이러한 종합적인 솔루션을 통해 연구자와 임상의는 단일 플랫폼을 통해 복잡한 유전체, 단백질체, 전사체 및 멀티오믹스 데이터 세트를 효율적으로 관리할 수 있게 되어, 워크플로우의 복잡성을 줄이고 업무 효율을 높일 수 있습니다. 생물학적 데이터의 양과 복잡성이 지속적으로 증가함에 따라, 확장 가능하고 통합된 바이오인포매틱스 플랫폼에 대한 수요로 인해 예측 기간 동안 엔드투엔드 솔루션 부문의 주도적 위상은 더욱 강화될 것으로 예측됩니다.
'부문별로는 의료 생명공학이 바이오인포매틱스 시장의 주요 점유율을 차지했습니다'
이 부문 내에서는 유전체학, 정밀의료, 분자진단, 신약 개발, 바이오마커 식별, 임상 연구에서의 바이오인포매틱스 활용 확대에 힘입어 의료 바이오기술이 가장 큰 점유율을 차지했습니다. 만성 질환, 암, 희귀 유전 질환의 유병률 증가는 맞춤형 치료 전략 및 첨단 분자진단을 지원하는 바이오인포매틱스 솔루션의 도입을 더욱 가속화하고 있습니다. 또한 차세대 염기서열 분석(NGS), 인공지능(AI), 머신러닝 및 클라우드 기반 바이오인포매틱스 플랫폼의 지속적인 발전으로 생물학적 데이터 분석의 속도, 확장성 및 정확도가 향상되었습니다. 생명과학 연구, 정밀 의학 이니셔티브 및 유전체 의학 프로그램에 대한 투자 증가로 인해, 예측 기간 동안 의료 생명공학 분야의 선도적 지위가 더욱 공고해질 것으로 예측됩니다.
'아시아태평양은 예측 기간 동안 가장 높은 성장률을 기록할 전망입니다.'
아시아태평양의 바이오인포매틱스 시장은 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 보일 것으로 전망됩니다. 이는 주로 중국, 인도, 일본, 한국, 싱가포르 등 신흥 경제국에서 유전체 연구, 정밀의료 및 생명공학에 대한 투자가 증가함에 따른 것입니다. 이 지역의 각국 정부는 자금 지원 이니셔티브, 국가 유전체 프로그램, 그리고 디지털 헬스케어 및 생명공학 혁신을 촉진하는 정책을 통해 유전체 및 생명과학 연구를 적극적으로 지원하고 있습니다.
Thermo Fisher Scientific Inc.(미국) 및 Illumina, Inc.(미국)는 바이오인포매틱스 시장의 주요 기업 중 일부입니다.
- 본 조사에서는 바이오정보학 시장의 이러한 주요 기업들에 대해 기업 프로파일, 최근 동향 및 주요 시장 전략을 포함한 상세한 경쟁 분석을 수행하고 있습니다.
조사 범위
본 조사 보고서에서는 바이오인포매틱스 시장을 제공 서비스별(소프트웨어 및 바이오인포매틱스 서비스), 기능별(데이터 분석, 구조·기능 분석, 멀티오믹스 통합, 임상 해석, 데이터 시각화·보고서 작성, 기타 기능), 이용 사례별(신약·의약품 개발, 정밀의료, 임상 진단, 바이오마커 발견, 연구·학술 용도, 기타 이용 사례), 부문별(의료 생명공학, 동물 생명공학, 식물 생명공학, 환경 생명공학, 법의학 생명공학, 기타 부문), 최종 사용자(제약·생명공학 기업, 학술·연구 기관, 병원·임상 진단실험실, 의약품 개발 수탁 기관(CRO) 및 의약품 개발·제조 수탁 기관(CDMO), 정부·공중보건 기관, 기타 최종 사용자), 지역(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카)별로 분류하고 있습니다. 본 보고서의 조사 범위에는 바이오정보학 시장의 성장에 영향을 미치는 주요 요인(촉진요인, 제약 요인, 과제, 기회 등)에 대한 상세한 정보가 포함되어 있습니다. 주요 업계 기업에 대한 상세한 분석을 통해 각 기업의 사업 개요, 솔루션, 주요 전략, 파트너십, 계약, 제품 및 서비스 출시, 합병·인수, 그리고 바이오인포매틱스 시장과 관련된 최근 동향에 대한 인사이트를 제공합니다. 또한, 본 보고서에서는 바이오인포매틱스 시장 생태계에서 두각을 나타내고 있는 스타트업 기업의 경쟁 분석에 대해서도 다루고 있습니다.
본 보고서를 구매해야 하는 이유
본 보고서는 시장을 선도하는 기업 및 신규 진출기업에게 바이오인포매틱스 시장 및 그 하위 부문의 매출에 관한 가장 정확한 추정치를 제공합니다. 이를 통해 이해관계자는 경쟁 구도를 이해하고, 자사의 비즈니스를 보다 효과적으로 포지셔닝하며, 적절한 시장 진출 전략을 수립하기 위한 인사이트를 얻을 수 있습니다. 또한, 본 보고서는 이해관계자가 시장 동향을 파악하는 데 도움을 주며, 주요 시장 성장 촉진요인 및 과제에 대한 정보를 제공합니다.
본 보고서에서는 다음 사항에 대한 인사이트를 제공합니다.
- 주요 성장 촉진요인(차세대 염기서열 분석(NGS) 도입 확대, 맞춤형 의료에 대한 수요 증가, 제약·바이오기술 분야의 연구개발비 증가, 바이오정보학에 대한 공공 및 민간 부문의 자금 지원 증가, 생명과학 분야에서의 AI 및 머신러닝 도입 확대) 및 제약 요인(바이오정보학 인프라의 높은 비용, 데이터 개인정보 보호, 보안, 규제 준수 관련 우려, 숙련된 바이오정보학 전문가 부족)에 대한 분석, 기회(신흥 시장의 수익성 높은 기회, 임상 바이오인포매틱스의 확대, 클라우드 및 연합형 바이오인포매틱스 플랫폼의 도입, 바이오인포매틱스 아웃소싱 서비스의 성장), 과제(방대한 데이터 양의 관리, 상호 운용성 및 멀티플랫폼 기능의 부재, 사내 개발 및 공개 도구에 의한 경쟁 심화, 멀티오믹스 데이터셋의 통합)
- 제품 개발/혁신 : 바이오정보학 시장의 향후 기술, 연구개발 활동, 신제품 출시에 대한 상세한 분석
- 시장 개발 : 수익성이 높은 시장에 대한 종합적인 정보 ? 본 보고서는 다양한 지역에 걸친 바이오인포매틱스 시장을 분석합니다.
- 시장 다각화 : 바이오인포매틱스 시장의 신제품, 미개척 지역, 최근 동향 및 투자에 대한 종합적인 정보
- 경쟁 분석 : 바이오인포매틱스 시장에서 Thermo Fisher Scientific Inc.(미국), Illumina, Inc.(미국), QIAGEN N.V.(네덜란드), Agilent Technologies, Inc.(미국), F. Hoffmann-La Roche Ltd.(스위스) 등 주요 기업의 시장 점유율, 성장 전략, 제품 라인업에 대한 상세한 평가.
자주 묻는 질문
목차
제1장 서론
제2장 주요 요약
제3장 프리미엄 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술 진보, AI의 영향, 특허, 혁신, 향후 응용
제7장 규제 상황
제8장 고객 현황과 구매 행동
제9장 바이오인포매틱스 시장(제공 제품별)
제10장 바이오인포매틱스 시장(기능별)
제11장 바이오인포매틱스 시장(이용 사례별)
제12장 바이오인포매틱스 시장(부문별)
제13장 바이오인포매틱스 시장(최종 사용자별)
제14장 바이오인포매틱스 시장(지역별)
제15장 경쟁 구도
제16장 기업 개요
제17장 조사 방법
제18장 부록
KTH 26.08.20The global bioinformatics market is projected to reach USD 34.41 billion by 2031, up from USD 18.63 billion in 2026, at a CAGR of 13.1% over the forecast period. Rapid growth in genomics research, precision medicine initiatives, and drug discovery programs has significantly increased demand for bioinformatics platforms that store, manage, analyze, and interpret complex biological datasets.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD MN/BN) |
| Segments | Offering, Function, Use Case, End User |
| Regions covered | North America, Asia Pacific, Europe, South America, Middle East & Africa |
Pharmaceutical and biotechnology companies, academic institutions, and healthcare organizations are increasingly adopting integrated bioinformatics solutions to accelerate research, improve clinical decision-making, and optimize therapeutic development. Furthermore, the growing digital transformation of life science research, coupled with rising investments in computational biology and cloud-based bioinformatics platforms, is improving workflow efficiency, enabling large-scale data sharing, and supporting collaborative research across organizations.
"End-to-end solutions projected to be the largest software segment in the bioinformatics market"
Software-based end-to-end solutions are expected to dominate market share during the forecast period. This dominance is driven by growing demand for integrated platforms that support complete bioinformatics workflows, including biological data acquisition, storage, processing, analysis, visualization, interpretation, and reporting. These comprehensive solutions enable researchers and clinicians to efficiently manage complex genomic, proteomic, transcriptomic, and multi-omics datasets through a single platform, reducing workflow complexity and improving operational efficiency. As the volume and complexity of biological data continue to increase, demand for scalable, integrated bioinformatics platforms is expected to further strengthen the leadership of the end-to-end solutions segment throughout the forecast period.
"By sector, medical biotechnology accounted for the major share of the bioinformatics market"
Within the sector, medical biotechnology accounted for the largest share, driven by the growing use of bioinformatics across genomics, precision medicine, molecular diagnostics, drug discovery, biomarker identification, and clinical research. The rising prevalence of chronic diseases, cancer, and rare genetic disorders has further accelerated the adoption of bioinformatics solutions to support personalized treatment strategies and advanced molecular diagnostics. In addition, ongoing advances in next-generation sequencing (NGS), artificial intelligence (AI), machine learning, and cloud-based bioinformatics platforms have improved the speed, scalability, and accuracy of biological data analysis. Increasing investments in life science research, precision medicine initiatives, and genomic medicine programs are expected to further reinforce the medical biotechnology segment's leading position throughout the forecast period.
"Asia Pacific to witness the fastest growth rate during the forecast period."
The bioinformatics market in Asia Pacific is projected to have the highest CAGR during the forecast period, primarily driven by rising investments in genomics research, precision medicine, and biotechnology across emerging economies such as China, India, Japan, South Korea, and Singapore. Governments in the region are actively supporting genomics and life sciences research through funding initiatives, national genomics programs, and policies that promote digital healthcare and biotechnology innovation.
The break-down of primary participants is as mentioned below:
- By Company Type - Tier 1: 46%, Tier 2: 34%, and Tier 3: 20%
- By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
- By Region - North America: 45%, Europe: 30%, Asia Pacific: 20%, Latin America: 3%, and Middle East & Africa: 2%.
Thermo Fisher Scientific Inc. (US) & Illumina, Inc. (US) are some of the key players in the bioinformatics market
- The study includes an in-depth competitive analysis of these key players in the bioinformatics market, with their company profiles, recent developments, and key market strategies.
Research Coverage
This research report categorizes the bioinformatics market by offerings (software & bioinformatics services), by function (data analysis, structural & functional analysis, multi-omics integration, clinical interpretation, data visualization & reporting, other functions), by use case (drug discovery & development, precision medicine, clinical diagnostics, biomarker discovery, research & academic applications, other use cases), by sector (medical biotechnology, animal biotechnology, plant biotechnology, environmental biotechnology, forensic biotechnology, other sectors), by end user (pharmaceutical & biotechnology companies, academic and research institutes, hospitals & clinical diagnostic laboratories, contract research organizations (CROs) & contract development and manufacturing organizations (CDMOs), government and public health organizations, other end users), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa). The scope of the report covers detailed information on the major factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the bioinformatics market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, partnerships, agreements, product and service launches, mergers and acquisitions, and recent developments associated with the bioinformatics market. The report also covers a competitive analysis of upcoming startups in the bioinformatics market ecosystem.
Reasons to buy this report
The report will provide market leaders and new entrants with the closest approximations of revenue figures for the bioinformatics market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights into the following pointers:
- Analysis of key drivers (increasing adoption of next-generation sequencing (NGS), growing demand for personalized medicine, rising pharmaceutical and biotechnology R&D expenditure, increasing public and private-sector funding for bioinformatics, increasing adoption of AI and machine learning in the life sciences), restraints (high cost of bioinformatics infrastructure, data privacy, security, and regulatory compliance concerns, shortage of skilled bioinformatics professionals), opportunities (lucrative opportunities in emerging markets, expansion of clinical bioinformatics, adoption of cloud and federated bioinformatics platforms, growth of bioinformatics outsourcing services), and challenges (management of large data volumes, lack of interoperability and multiplatform capabilities, growing competition from in-house development and publicly available tools, integration of multi-omics datasets)
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the bioinformatics market
- Market Development: Comprehensive information about lucrative markets - the report analyzes the bioinformatics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioinformatics market
- Competitive Assessment: In-depth assessment of market share, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), among others, in the bioinformatics market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 BIOINFORMATICS MARKET OVERVIEW
- 3.2 BIOINFORMATICS MARKET, BY OFFERING & REGION
- 3.3 BIOINFORMATICS MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Increasing adoption of next-generation sequencing (NGS)
- 4.2.1.2 Growing demand for personalized medicine
- 4.2.1.3 Increasing pharmaceutical and biotechnology R&D expenditure
- 4.2.1.4 Increasing public and private-sector funding for bioinformatics
- 4.2.1.5 Increasing adoption of AI and machine learning in life sciences
- 4.2.1.6 Decreasing cost of genome sequencing
- 4.2.2 RESTRAINTS
- 4.2.2.1 High cost of bioinformatics infrastructure
- 4.2.2.2 Data privacy, security, and regulatory compliance concerns
- 4.2.2.3 Shortage of skilled bioinformatics professionals
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Lucrative opportunities in emerging markets
- 4.2.3.2 Expansion of clinical bioinformatics
- 4.2.3.3 Adoption of cloud and federated bioinformatics platforms
- 4.2.3.4 Growth of bioinformatics outsourcing services
- 4.2.4 CHALLENGES
- 4.2.4.1 Management of large data volumes
- 4.2.4.2 Lack of interoperability and multiplatform capabilities
- 4.2.4.3 Growing competition from in-house development and publicly available tools
- 4.2.4.4 Integration of multiomics datasets
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 THREAT OF SUBSTITUTES
- 5.1.3 BARGAINING POWER OF SUPPLIERS
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
- 5.3 VALUE CHAIN ANALYSIS
- 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
- 5.3.2 TECHNOLOGY INFRASTRUCTURE
- 5.3.3 PLATFORM DEVELOPMENT
- 5.3.4 DISTRIBUTION
- 5.3.5 MARKETING & SALES
- 5.3.6 POST-SALE SERVICES
- 5.4 ECOSYSTEM ANALYSIS
- 5.5 PRICING ANALYSIS
- 5.5.1 INDICATIVE PRICING FOR BIOINFORMATICS MARKET, BY OFFERING (2025)
- 5.5.2 INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY REGION (2025)
- 5.6 KEY CONFERENCES AND EVENTS, 2026-2027
- 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.8 INVESTMENT AND FUNDING SCENARIO
- 5.9 CASE STUDY ANALYSIS
- 5.10 IMPACT OF 2025 US TARIFF -BIOINFORMATICS MARKET
- 5.10.1 INTRODUCTION
- 5.10.2 KEY TARIFF RATES
- 5.10.3 PRICE IMPACT ANALYSIS
- 5.10.4 IMPACT ON COUNTRY/REGION
- 5.10.4.1 US
- 5.10.4.2 Europe
- 5.10.4.3 Asia Pacific
- 5.10.5 IMPACT ON END USERS
- 5.10.5.1 Pharmaceutical & biotechnology companies
- 5.10.5.2 Academic & research institutes
- 5.10.5.3 Hospitals & clinical diagnostic laboratories
- 5.10.5.4 Contract research organizations and contract development & manufacturing organizations
- 5.10.5.5 Government & public health organizations
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 NEXT-GENERATION SEQUENCING TECHNOLOGIES
- 6.1.2 ARTIFICIAL INTELLIGENCE & MACHINE LEARNING
- 6.1.3 MULTIOMICS ANALYSIS PLATFORMS
- 6.1.4 VARIANT INTERPRETATION & CLINICAL DECISION SUPPORT
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 GENERATIVE AI FOR BIOINFORMATICS
- 6.2.2 AI-BASED DRUG DISCOVERY PLATFORMS
- 6.2.3 LARGE LANGUAGE MODELS FOR LIFE SCIENCES
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 HIGH-PERFORMANCE COMPUTING
- 6.3.2 BIG DATA ANALYTICS
- 6.3.3 BLOCKCHAIN TECHNOLOGY
- 6.3.4 ROBOTICS & LABORATORY AUTOMATION
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 PATENT PUBLICATION TRENDS FOR BIOINFORMATICS MARKET
- 6.5.2 BIOINFORMATICS PATENTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 6.6 FUTURE APPLICATIONS
- 6.6.1 AI-DRIVEN GENOMIC INTERPRETATION & CLINICAL DECISION SUPPORT
- 6.6.2 PRECISION MEDICINE & MULTIOMICS INTEGRATION
- 6.6.3 INTEGRATED BIOINFORMATICS FOR DRUG DISCOVERY & CLINICAL RESEARCH
- 6.7 IMPACT OF GEN AI IN BIOINFORMATICS MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN BIOINFORMATICS MARKET
- 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
- 6.7.3.1 AI-powered genomics for precision medicine at Illumina and Tempus AI
- 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
- 6.7.4.1 AI in bioinformatics software market
- 6.7.4.2 Next-generation sequencing market
- 6.7.4.3 Drug discovery market
- 6.7.5 USERS READINESS AND IMPACT ASSESSMENT
- 6.7.5.1 User readiness
- 6.7.5.1.1 Pharmaceutical & biotechnology companies
- 6.7.5.1.2 Academic & research institutes
- 6.7.5.1.3 Hospitals & clinical diagnostic laboratories
- 6.7.5.1.4 Contract research organizations and contract development & manufacturing organizations
- 6.7.5.2 Impact assessment
- 6.7.5.2.1 User A: Pharmaceutical & biotechnology companies
- 6.7.5.2.1.1 Implementation
- 6.7.5.2.1.2 Impact
- 6.7.5.2.2 User B: Academic & Research Institutes
- 6.7.5.2.2.1 Implementation
- 6.7.5.2.2.2 Impact
- 6.7.5.2.3 User C: Hospitals & Clinical Diagnostic Laboratories
- 6.7.5.2.3.1 Implementation
- 6.7.5.2.3.2 Impact
- 6.7.5.2.4 User D: Contract research organizations and contract development & manufacturing organizations
- 6.7.5.2.4.1 Implementation
- 6.7.5.2.4.2 Impact
- 6.7.5.2.1 User A: Pharmaceutical & biotechnology companies
- 6.7.5.1 User readiness
7 REGULATORY LANDSCAPE
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 REGULATORY FRAMEWORK
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 Asia Pacific
- 7.1.2.4 Latin America
- 7.1.2.5 Middle East & Africa
- 7.1.3 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 INTRODUCTION
- 8.2 DECISION-MAKING PROCESS
- 8.3 STAKEHOLDERS AND BUYING EVALUATION CRITERIA
- 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.3.2 BUYING CRITERIA
- 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.5 UNMET NEEDS FROM VARIOUS END USERS
- 8.5.1 UNMET NEEDS
- 8.5.2 END USER EXPECTATIONS
- 8.6 MARKET PROFITABILITY
9 BIOINFORMATICS MARKET, BY OFFERING
- 9.1 INTRODUCTION
- 9.2 SOFTWARE
- 9.2.1 NICHE POINT SOLUTIONS
- 9.2.1.1 Increasing adoption of NGS and multiomics technologies to boost growth
- 9.2.2 KNOWLEDGE MANAGEMENT TOOLS
- 9.2.2.1 Rising demand for genomic variant interpretation databases
- 9.2.2.2 Generalized knowledge management tools
- 9.2.2.2.1 Development of novel generalized knowledge management tools to drive growth
- 9.2.2.3 Specialized knowledge management tools
- 9.2.2.3.1 Data security and highly reliable information storage systems to support growth
- 9.2.3 END-TO-END SOLUTIONS
- 9.2.3.1 Integration of artificial intelligence (AI) and machine learning (ML) to drive growth
- 9.2.3.2 Genomic solutions
- 9.2.3.2.1 Expansion of precision medicine and genomic diagnostics - segment driver
- 9.2.3.3 Multiomics solutions
- 9.2.3.3.1 Increasing integration of genomics, transcriptomics, proteomics, and metabolomics dataset to drive market
- 9.2.3.4 Chemoinformatics solutions
- 9.2.3.4.1 Increasing investment in R&D to boost segment
- 9.2.3.5 Proteomics solutions
- 9.2.3.5.1 Growing focus on protein biomarker discovery fuels adoption
- 9.2.3.6 Transcriptomics solutions
- 9.2.3.6.1 Rising demand for gene expression analysis accelerates adoption
- 9.2.3.7 Metabolomics solutions
- 9.2.3.7.1 Adoption of LC-MS and GC-MS technologies accelerates segment growth
- 9.2.3.8 Other end-to-end Solutions
- 9.2.1 NICHE POINT SOLUTIONS
- 9.3 SERVICES
- 9.3.1 SEQUENCING & DATA GENERATION
- 9.3.1.1 Increasing adoption of NGS drives demand
- 9.3.2 DATA ANALYSIS & INTERPRETATION
- 9.3.2.1 Growing complexity of multiomics data drives demand
- 9.3.3 DRUG DISCOVERY & TARGET IDENTIFICATION
- 9.3.3.1 Increasing adoption of precision medicine fuels demand
- 9.3.4 DATABASE & DATA MANAGEMENT
- 9.3.4.1 Exponential growth of biological data drives segment
- 9.3.5 CLOUD & MANAGED BIOINFORMATICS
- 9.3.5.1 Increasing adoption of cloud computing accelerates segment growth
- 9.3.6 CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT
- 9.3.6.1 Increasing demand for customized bioinformatics workflows boosts segment
- 9.3.7 OTHER SERVICES
- 9.3.1 SEQUENCING & DATA GENERATION
10 BIOINFORMATICS MARKET, BY FUNCTION
- 10.1 INTRODUCTION
- 10.2 DATA ANALYSIS
- 10.2.1 SEQUENCE ANALYSIS
- 10.2.1.1 Growing volume of sequencing data drives demand
- 10.2.2 VARIANT ANALYSIS
- 10.2.2.1 Increasing adoption of precision medicine to boost segment
- 10.2.3 GENE EXPRESSION ANALYSIS
- 10.2.3.1 Expanding transcriptomics research drives segment growth
- 10.2.4 OTHER DATA ANALYSIS FUNCTIONS
- 10.2.1 SEQUENCE ANALYSIS
- 10.3 STRUCTURAL & FUNCTIONAL ANALYSIS
- 10.3.1 GROWING ADOPTION OF STRUCTURE-BASED DRUG DISCOVERY AND PROTEIN MODELING TO BOOST GROWTH
- 10.4 MULTIOMICS INTEGRATION
- 10.4.1 INCREASING INTEGRATION OF MULTIOMICS DATA DRIVES DEMAND FOR ADVANCED BIOINFORMATICS PLATFORMS
- 10.5 CLINICAL INTERPRETATION
- 10.5.1 GROWING ADOPTION OF PRECISION MEDICINE AND CLINICAL GENOMICS IS PROPELS GROWTH
- 10.6 DATA VISUALIZATION & REPORTING
- 10.6.1 INCREASING ADOPTION OF AI-DRIVEN DRUG DISCOVERY AND COMPUTATIONAL CHEMISTRY - KEY SEGMENT DRIVER
- 10.7 OTHER FUNCTIONS
11 BIOINFORMATICS MARKET, BY USE CASE
- 11.1 INTRODUCTION
- 11.2 DRUG DISCOVERY & DEVELOPMENT
- 11.2.1 GROWING PHARMACEUTICAL R&D INVESTMENTS DRIVE GROWTH
- 11.3 PRECISION MEDICINE
- 11.3.1 INCREASING DEMAND FOR PERSONALIZED TREATMENT STRATEGIES TO BOOST SEGMENT
- 11.4 CLINICAL DIAGNOSTICS
- 11.4.1 GROWING ADOPTION OF GENOMIC TESTING - KEY DRIVER
- 11.5 BIOMARKER DISCOVERY
- 11.5.1 GROWING FOCUS ON PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO BOOST SEGMENT
- 11.6 RESEARCH & ACADEMIC APPLICATIONS
- 11.6.1 INCREASING INVESTMENTS IN LIFE SCIENCE RESEARCH PROPEL SEGMENT GROWTH
- 11.7 OTHER USE CASES
12 BIOINFORMATICS MARKET, BY SECTOR
- 12.1 INTRODUCTION
- 12.2 MEDICAL BIOTECHNOLOGY
- 12.2.1 EXPANSION OF GENOMIC DIAGNOSTICS, MOLECULAR TESTING, AND PERSONALIZED HEALTHCARE TO DRIVE SEGMENT
- 12.3 ANIMAL BIOTECHNOLOGY
- 12.3.1 INCREASING ADOPTION OF PRECISION LIVESTOCK FARMING AND VETERINARY GENOMICS TO PROPEL GROWTH
- 12.4 PLANT BIOTECHNOLOGY
- 12.4.1 GROWING DEMAND FOR CLIMATE-RESILIENT AND HIGH-YIELD CROPS TO BOOST SEGMENT
- 12.5 ENVIRONMENTAL BIOTECHNOLOGY
- 12.5.1 INCREASING ADOPTION OF ENVIRONMENTAL DNA (EDNA) AND METAGENOMICS BOOSTS GROWTH
- 12.6 FORENSIC BIOTECHNOLOGY
- 12.6.1 INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING AND FORENSIC GENOMICS TO DRIVE SEGMENT
- 12.7 OTHER SECTORS
13 BIOINFORMATICS MARKET, BY END USER
- 13.1 INTRODUCTION
- 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 13.2.1 INCREASING PHARMACEUTICAL R&D INVESTMENTS AND ADOPTION OF ADVANCED COMPUTATIONAL TECHNOLOGIES
- 13.3 ACADEMIC & RESEARCH INSTITUTES
- 13.3.1 GROWING GOVERNMENT FUNDING FOR BIOMEDICAL RESEARCH DRIVES SEGMENT
- 13.4 HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES
- 13.4.1 INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
- 13.5 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
- 13.5.1 INCREASING OUTSOURCING OF DRUG DEVELOPMENT AND GROWING DEMAND FOR SPECIALIZED COMPUTATIONAL EXPERTISE
- 13.6 GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS
- 13.6.1 INCREASING INVESTMENTS IN GENOMIC SURVEILLANCE AND PUBLIC HEALTH INFORMATICS
- 13.7 OTHER END USERS
14 BIOINFORMATICS MARKET, BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 14.2.2 US
- 14.2.2.1 Strong government support and rapid advances in genomics and AI drive market
- 14.2.3 CANADA
- 14.2.3.1 Increasing government investments in genomics and national bioinformatics infrastructure
- 14.3 EUROPE
- 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 14.3.2 GERMANY
- 14.3.2.1 Strong government investments in precision medicine and expanding AI-enabled bioinformatics research
- 14.3.3 UK
- 14.3.3.1 Strategic initiatives and funding for genomics research to support market growth
- 14.3.4 FRANCE
- 14.3.4.1 Market driven by national genomics programs and AI-enabled biomedical research
- 14.3.5 ITALY
- 14.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology
- 14.3.6 SPAIN
- 14.3.6.1 Growing focus on advancements in personalized medicine to support market growth
- 14.3.7 REST OF EUROPE
- 14.4 ASIA PACIFIC
- 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 14.4.2 CHINA
- 14.4.2.1 Expansion of national genomic data infrastructure drives market
- 14.4.3 JAPAN
- 14.4.3.1 Rising number of collaborations in bioinformatics to drive market
- 14.4.4 INDIA
- 14.4.4.1 Government and private initiatives for genomics projects to propel market
- 14.4.5 AUSTRALIA
- 14.4.5.1 Increased genetic research to support market growth
- 14.4.6 SOUTH KOREA
- 14.4.6.1 National biomedical data integration and AI-driven precision medicine accelerate market
- 14.4.7 REST OF ASIA PACIFIC
- 14.5 LATIN AMERICA
- 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 14.5.2 BRAZIL
- 14.5.2.1 Increased government investments in genomics advancements to drive market
- 14.5.3 MEXICO
- 14.5.3.1 Rising demand for chronic disease treatment to support growth
- 14.5.4 REST OF LATIN AMERICA
- 14.6 MIDDLE EAST & AFRICA
- 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 14.6.2 GCC COUNTRIES
- 14.6.2.1 Saudi Arabia
- 14.6.2.1.1 Growing healthcare expenditure to boost market growth
- 14.6.2.2 UAE
- 14.6.2.2.1 Collaborations to advance genome sequencing and market growth
- 14.6.2.3 Rest of GCC
- 14.6.2.1 Saudi Arabia
- 14.6.3 SOUTH AFRICA
- 14.6.3.1 Growing focus on precision medicine to propel market
- 14.6.4 REST OF MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
- 15.1 OVERVIEW
- 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
- 15.3 REVENUE ANALYSIS, 2021-2025
- 15.4 MARKET SHARE ANALYSIS, 2025
- 15.5 BRAND COMPARISON
- 15.6 COMPANY VALUATION AND FINANCIAL METRICS
- 15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 15.7.1 STARS
- 15.7.2 EMERGING LEADERS
- 15.7.3 PERVASIVE PLAYERS
- 15.7.4 PARTICIPANTS
- 15.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 15.7.5.1 Company footprint
- 15.7.5.2 Region footprint
- 15.7.5.3 Offering footprint
- 15.7.5.4 Function footprint
- 15.7.5.5 Use case footprint
- 15.7.5.6 End user footprint
- 15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.8.1 PROGRESSIVE COMPANIES
- 15.8.2 RESPONSIVE COMPANIES
- 15.8.3 DYNAMIC COMPANIES
- 15.8.4 STARTING BLOCKS
- 15.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 15.8.5.1 List of startups/SMES
- 15.8.5.2 Competitive benchmarking of Startups/SMEs
- 15.9 COMPETITIVE SCENARIO
- 15.9.1 PRODUCT LAUNCHES & ENHANCEMENTS
- 15.9.2 DEALS
- 15.9.3 EXPANSIONS
- 15.9.4 OTHER DEVELOPMENTS
16 COMPANY PROFILES
- 16.1 KEY COMPANIES
- 16.1.1 THERMO FISHER SCIENTIFIC INC.
- 16.1.1.1 Business overview
- 16.1.1.2 Products/Services offered
- 16.1.1.3 Recent developments
- 16.1.1.3.1 Product launches
- 16.1.1.3.2 Deals
- 16.1.1.3.3 Expansions
- 16.1.1.4 MnM view
- 16.1.1.4.1 Key strengths
- 16.1.1.4.2 Strategic choices
- 16.1.1.4.3 Weaknesses and competitive threats
- 16.1.2 ILLUMINA, INC.
- 16.1.2.1 Business overview
- 16.1.2.2 Products/Services offered
- 16.1.2.3 Recent developments
- 16.1.2.3.1 Product launches
- 16.1.2.3.2 Deals
- 16.1.2.3.3 Expansions
- 16.1.2.4 MnM view
- 16.1.2.4.1 Key strengths
- 16.1.2.4.2 Strategic choices
- 16.1.2.4.3 Weaknesses and competitive threats
- 16.1.3 QIAGEN N.V.
- 16.1.3.1 Business overview
- 16.1.3.2 Products/services offered
- 16.1.3.3 Recent developments
- 16.1.3.3.1 Product launches & enhancements
- 16.1.3.3.2 Deals
- 16.1.3.3.3 Other developments
- 16.1.3.3.4 Expansions
- 16.1.3.4 MnM view
- 16.1.3.4.1 Key strengths
- 16.1.3.4.2 Strategic choices
- 16.1.3.4.3 Weaknesses and competitive threats
- 16.1.4 AGILENT TECHNOLOGIES, INC.
- 16.1.4.1 Business overview
- 16.1.4.2 Products/Services offered
- 16.1.4.3 Recent developments
- 16.1.4.3.1 Deals
- 16.1.4.4 MnM view
- 16.1.4.4.1 Key strengths
- 16.1.4.4.2 Strategic choices
- 16.1.4.4.3 Weaknesses and competitive threats
- 16.1.5 F. HOFFMANN-LA ROCHE LTD.
- 16.1.5.1 Business overview
- 16.1.5.2 Products/Services offered
- 16.1.5.3 Recent developments
- 16.1.5.3.1 Product launches
- 16.1.5.3.2 Deals
- 16.1.5.3.3 Other developments
- 16.1.5.4 MnM view
- 16.1.5.4.1 Key strengths
- 16.1.5.4.2 Strategic choices
- 16.1.5.4.3 Weaknesses and competitive threats
- 16.1.6 REVVITY, INC.
- 16.1.6.1 Business overview
- 16.1.6.2 Products/Services offered
- 16.1.6.3 Recent developments
- 16.1.6.3.1 Product launches
- 16.1.6.3.2 Deals
- 16.1.6.3.3 Expansions
- 16.1.7 EUROFINS SCIENTIFIC
- 16.1.7.1 Business overview
- 16.1.7.2 Products/services offered
- 16.1.7.3 Recent developments
- 16.1.7.3.1 Deals
- 16.1.7.3.2 Expansions
- 16.1.8 BGI GENOMICS
- 16.1.8.1 Business overview
- 16.1.8.2 Products/services offered
- 16.1.8.3 Recent developments
- 16.1.8.3.1 Deals
- 16.1.9 WATERS CORPORATION
- 16.1.9.1 Business overview
- 16.1.9.2 Products/services offered
- 16.1.10 DNANEXUS, INC.
- 16.1.10.1 Business overview
- 16.1.10.2 Products/services offered
- 16.1.10.3 Recent developments
- 16.1.10.3.1 Product launches
- 16.1.10.3.2 Deals
- 16.1.10.3.3 Other developments
- 16.1.11 OXFORD NANOPORE TECHNOLOGIES PLC
- 16.1.11.1 Business overview
- 16.1.11.2 Products/Services offered
- 16.1.11.3 Recent developments
- 16.1.11.3.1 Deals
- 16.1.11.3.2 Expansions
- 16.1.12 10X GENOMICS
- 16.1.12.1 Business overview
- 16.1.12.2 Products/Services offered
- 16.1.12.3 Recent developments
- 16.1.12.3.1 Deals
- 16.1.13 PACBIO
- 16.1.13.1 Business overview
- 16.1.13.2 Products/Services offered
- 16.1.13.3 Recent developments
- 16.1.13.3.1 Product launches
- 16.1.13.3.2 Deals
- 16.1.13.3.3 Expansions
- 16.1.14 SIEMENS AG
- 16.1.14.1 Business overview
- 16.1.14.2 Products/Services offered
- 16.1.14.3 Recent developments
- 16.1.14.3.1 Product launches
- 16.1.14.3.2 Deals
- 16.1.14.3.3 Other developments
- 16.1.15 SOPHIA GENETICS
- 16.1.15.1 Business overview
- 16.1.15.2 Products/Services offered
- 16.1.15.3 Recent developments
- 16.1.15.3.1 Product Launches
- 16.1.15.3.2 Deals
- 16.1.15.3.3 Other developments
- 16.1.16 EXCELRA
- 16.1.16.1 Business overview
- 16.1.16.2 Products/Services offered
- 16.1.16.3 Recent developments
- 16.1.16.3.1 Product Enhancement
- 16.1.16.3.2 Deals
- 16.1.17 GENEWIZ (AZENTA LIFE SCIENCES)
- 16.1.17.1 Business overview
- 16.1.17.2 Products/Services offered
- 16.1.17.3 Recent developments
- 16.1.17.3.1 Deals
- 16.1.17.3.2 Other developments
- 16.1.18 ONTOFORCE
- 16.1.18.1 Business overview
- 16.1.18.2 Products/Services offered
- 16.1.18.3 Recent developments
- 16.1.18.3.1 Product launches & enhancements
- 16.1.18.3.2 Deals
- 16.1.19 VELSERA INC.
- 16.1.19.1 Business overview
- 16.1.19.2 Products/Services offered
- 16.1.19.3 Recent developments
- 16.1.19.3.1 Deals
- 16.1.20 SEQERA
- 16.1.20.1 Business overview
- 16.1.20.2 Products/Services offered
- 16.1.20.3 Recent developments
- 16.1.20.3.1 Product launches & enhancement
- 16.1.20.3.2 Deals
- 16.1.20.3.3 Other developments
- 16.1.1 THERMO FISHER SCIENTIFIC INC.
- 16.2 OTHER PLAYERS
- 16.2.1 DNASTAR
- 16.2.2 FIOS GENOMICS
- 16.2.3 DEEP GENOMICS
- 16.2.4 PSOMAGEN
- 16.2.5 SOURCE BIOSCIENCE
17 RESEARCH METHODOLOGY
- 17.1 RESEARCH APPROACH
- 17.1.1 SECONDARY RESEARCH
- 17.1.1.1 Key data from secondary sources
- 17.1.2 PRIMARY RESEARCH
- 17.1.2.1 Key data from primary sources
- 17.1.2.2 Breakdown of primaries
- 17.1.2.3 Insights from primary experts
- 17.1.1 SECONDARY RESEARCH
- 17.2 RESEARCH METHODOLOGY DESIGN
- 17.3 MARKET SIZE ESTIMATION
- 17.4 MARKET BREAKDOWN DATA TRIANGULATION
- 17.5 MARKET SHARE ESTIMATION
- 17.6 STUDY ASSUMPTIONS
- 17.7 RESEARCH LIMITATIONS
- 17.7.1 METHODOLOGY-RELATED LIMITATIONS
- 17.7.2 SCOPE-RELATED LIMITATIONS
- 17.8 RISK ASSESSMENT
18 APPENDIX
- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS
